Clinical Trials Directory

Trials / Completed

CompletedNCT02579239

Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD)

An Open-Label, Intrapatient Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Limb Girdle and Facioscapulohumeral Muscular Dystrophies

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
18 (actual)
Sponsor
aTyr Pharma, Inc. · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to assess the safety and biological activity of ATYR1940 in participants with LGMD2B and FSHD.

Conditions

Interventions

TypeNameDescription
BIOLOGICALATYR1940Concentrate for solution for infusion
BIOLOGICALPlaceboConcentrate for solution for infusion

Timeline

Start date
2015-11-30
Primary completion
2016-10-05
Completion
2016-10-05
First posted
2015-10-19
Last updated
2023-10-19
Results posted
2023-10-19

Locations

6 sites across 3 countries: United States, Denmark, France

Source: ClinicalTrials.gov record NCT02579239. Inclusion in this directory is not an endorsement.